Rothschild & Co Redburn raised the firm’s price target on Smith & Nephew to 1,445 GBp from 1,270 GBp and keeps a Neutral rating on the shares. The firm sees competitive challenges in the company’s orthopedics segment offsetting improved execution and strength in sports medicine.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith & Nephew announces new evidence, market updates on REGENETEN
- Smith & Nephew Announces Share Sale by Chief Compliance Officer
- Smith & Nephew Announces Share Sale by Executive
- Smith & Nephew announces U.S. launch of CENTRIO platelet-rich-plasma system
- Smith & Nephew Announces Updated Share Capital Structure